Adoram Therapeutics: Funding, Investors & Team (Sep 2026)
Adoram Therapeutics is developing a suite of therapies with an allosteric molecular mode of action, which can either positively or negatively modulate the signaling of specific GPCRs - the largest class of human receptors. Our foremost asset is a small molecule immunotherapy to treat patients with solid tumors. Thanks to its unique allosteric mode of action, this 3rd generation adenosine 2A receptor antagonist retains its potency in high adenosine (immunosuppressive) microenvironments, such as those found in many solid tumors, and is therefore intended to be used as a treatment for a wide range of cancers.
Adoram Therapeutics has raised $1.4M across 3 funding rounds on record, the most recent an undisclosed round of $1.3M announced in May 2025.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Adoram Therapeutics Company Profile and Key Stats
Latest funding round on record: May 2025.
Adoram Therapeutics Funding Rounds
1 of 3 rounds was announced without a disclosed amount and is excluded from the total.
Adoram Therapeutics raised $120k in an undisclosed round announced in Oct 2024.
4 months later, a Pre-Seed was announced in Feb 2025 with no disclosed amount.
3 months later, an undisclosed round of $1.3M was announced in May 2025.
Adoram Therapeutics Founders and Leadership Team
Contact details for the Adoram Therapeutics team: 2 of 2 have an email address on file.
Start 14-day free trial →Adoram Therapeutics Funding Compared to Other Biotechnology Startups
Adoram Therapeutics' latest round of $1.3M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Adoram Therapeutics in Biotechnology and Swiss
Companies Similar to Adoram Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Adoram Therapeutics Funding FAQs
What does Adoram Therapeutics do?
Adoram Therapeutics is developing a suite of therapies with an allosteric molecular mode of action, which can either positively or negatively modulate the signaling of specific GPCRs - the largest class of human receptors. Our foremost asset is a small molecule immunotherapy to treat patients with solid tumors. Thanks to its unique allosteric mode of action, this 3rd generation adenosine 2A receptor antagonist retains its potency in high adenosine (immunosuppressive) microenvironments, such as those found in many solid tumors, and is therefore intended to be used as a treatment for a wide range of cancers.
How much funding has Adoram Therapeutics raised?
Adoram Therapeutics has raised $1.4M across 3 rounds on record. The most recent is an undisclosed round of $1.3M announced in May 2025.
When did Adoram Therapeutics last raise funding?
Adoram Therapeutics' most recent funding round on record is an undisclosed round of $1.3M, announced in May 2025.
Who founded Adoram Therapeutics?
FundedIQ lists Hesham Hamed (Founder), Leonardo Scapozza (Founder) at Adoram Therapeutics.
Where is Adoram Therapeutics headquartered?
Adoram Therapeutics is based in Swiss, West Virginia, United States.
How many employees does Adoram Therapeutics have?
Adoram Therapeutics is in the 1-10 employee band.
How does Adoram Therapeutics' funding compare to other Biotechnology startups?
Adoram Therapeutics' latest round of $1.3M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Adoram Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Adoram Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.